Literature DB >> 17432926

Pharmacotherapy for nocturia in the elderly patient.

Ragnar Asplund1.   

Abstract

Nocturia may be attributable to nocturnal polyuria (nocturnal urine overproduction), a diminished nocturnal bladder capacity or a combination of the two conditions.A disorder of the vasopressin (antidiuretic hormone) system with very low or undetectable levels of vasopressin at night, affecting some elderly people, may cause an increase in the nocturnal urine output, which in the most extreme cases accounts for 85% of the 24-hour diuresis. The increased urine output can be treated with desmopressin orally at bedtime, generally using low doses. Self-imposed fluid restrictions before bedtime are not effective in reducing the nocturnal urine output in this condition. Nocturia is also more prevalent in association with a reduced bladder capacity. Antimuscarinic drugs are used in attempts to depress involuntary bladder contractions. Decreased nocturnal voided volumes in men and consequent increased nocturia may suggest difficulty in emptying the bladder or detrusor overactivity. alpha(1)-Adrenoceptor antagonists and 5alpha-reductase inhibitors are often used in men with symptoms indicative of benign prostatic hyperplasia, and one of their effects is reduction of nocturia. In women, estrogen deficiency, a common consequence of the menopausal transition, causes atrophic changes within the urogenital tract. Consequently, such women are more disposed to having urogenital symptoms, among them nocturia. This review emphasises the importance of correctly diagnosing and treating nocturia in elderly patients. This will improve patients' sleep and, in turn, reduce their risk of fall injuries and the associated detrimental consequences, thereby improving patients' health and quality of life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432926     DOI: 10.2165/00002512-200724040-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  84 in total

Review 1.  Renal regulation of urine volume: potential implications for nocturia.

Authors:  G L Robertson; J P Norgaard
Journal:  BJU Int       Date:  2002-12       Impact factor: 5.588

2.  Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.

Authors:  Asa Rembratt; Charlotte Graugaard-Jensen; Thomas Senderovitz; Jens Peter Norgaard; Jens Christian Djurhuus
Journal:  Eur J Clin Pharmacol       Date:  2004-06-09       Impact factor: 2.953

3.  Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study.

Authors:  W Dorschner; J U Stolzenburg; R Griebenow; M Halaska; G Schubert; G Mürtz; M Frank; F Wieners
Journal:  Eur Urol       Date:  2000-06       Impact factor: 20.096

4.  A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo.

Authors:  J M Reynard; A Cannon; Q Yang; P Abrams
Journal:  Br J Urol       Date:  1998-02

Review 5.  Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.

Authors:  Michael Marberger
Journal:  Nat Clin Pract Urol       Date:  2006-09

6.  Assessment of cognitive function of the elderly population: effects of darifenacin.

Authors:  Richard B Lipton; Ken Kolodner; Keith Wesnes
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

7.  Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up.

Authors:  Mary Amanda Dew; Carolyn C Hoch; Daniel J Buysse; Timothy H Monk; Amy E Begley; Patricia R Houck; Martica Hall; David J Kupfer; Charles F Reynolds
Journal:  Psychosom Med       Date:  2003 Jan-Feb       Impact factor: 4.312

8.  Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.

Authors:  K M Hughes; J C Lang; R Lazare; D Gordon; S L Stanton; J Malone-Lee; M Geraint
Journal:  Xenobiotica       Date:  1992-07       Impact factor: 1.908

9.  A double-blind crossover trial of baclofen--a new treatment for the unstable bladder syndrome.

Authors:  M C Taylor; C P Bates
Journal:  Br J Urol       Date:  1979-12

Review 10.  Nocturia.

Authors:  Jeffrey P Weiss; Jerry G Blaivas
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 2.862

View more
  7 in total

Review 1.  Nocturia × disturbed sleep: a review.

Authors:  Daniele Furtado; Helena Hachul; Monica L Andersen; Rodrigo A Castro; Manoel B Girão; Sergio Tufik
Journal:  Int Urogynecol J       Date:  2011-08-17       Impact factor: 2.894

2.  Managing Nocturia in Frail Older Adults.

Authors:  Dylan T Wolff; Kerry A Adler; Corey S Weinstein; Jeffrey P Weiss
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

3.  Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy.

Authors:  M P Fitzgerald; G Lemack; T Wheeler; H J Litman
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-08-14

4.  Safety and efficacy of desmopressin for the treatment of nocturia in elderly patients: a cohort study.

Authors:  Miho Song; Bum Sik Hong; Ji-Youn Chun; Ji-Yeon Han; Myung-Soo Choo
Journal:  Int Urol Nephrol       Date:  2014-03-05       Impact factor: 2.370

5.  Efficacy of desmopressin in treatment of nocturia in elderly men.

Authors:  Bijan Rezakhaniha; Nahid Arianpour; Soheila Siroosbakhat
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

6.  Self-reported sleep disturbances in renal transplant recipients.

Authors:  Hanna Burkhalter; Daniel P Brunner; Anna Wirz-Justice; Christian Cajochen; Terri E Weaver; Jürg Steiger; Thomas Fehr; Reto M Venzin; Sabina De Geest
Journal:  BMC Nephrol       Date:  2013-10-10       Impact factor: 2.388

Review 7.  Medication adherence in the management of nocturia: challenges and solutions.

Authors:  Ravishankar Jayadevappa; Diane K Newman; Sumedha Chhatre; Alan J Wein
Journal:  Patient Prefer Adherence       Date:  2015-01-13       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.